Panagora Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Panagora Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-43	Closed	-$2K	–	2432
2021 Q2	$2K	Hold	43	–	–	﹤0.01%	2651
2021 Q1	$3K	Hold	43	–	–	﹤0.01%	2680
2020 Q4	$5K	Buy	+43	New	+$3.92K	﹤0.01%	2486
2019 Q1	–	Sell	-9,421	Closed	-$525K	–	2586
2018 Q4	$525K	Hold	9,421	–	–	﹤0.01%	1319
2018 Q3	$1.12M	Hold	9,421	–	–	﹤0.01%	1079
2018 Q2	$962K	Buy	+9,421	New	+$1.17M	﹤0.01%	1156
2017 Q3	–	Sell	-115	Closed	-$18K	–	2519
2017 Q2	$18K	Buy	+115	New	+$18.1K	﹤0.01%	2303

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Panagora Asset Management's SYRS Position: Q3 2021 in Review

Panagora Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2021, closing a stake of 43 shares — an estimated $2K sold.

Panagora Asset Management first reported a position in SYRS in Q2 2017 and held it in 7 quarters. The position peaked at $1.12M in Q3 2018. 100 funds tracked by Wall St. Rank hold SYRS as of Q3 2021.

Panagora Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Panagora Asset Management sold 43 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $2K.
Panagora Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 7 quarters.
Panagora Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.12M in Q3 2018.
100 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.